-
H.C. Wainwright Reiterates Buy Rating on Assembly Biosciences (ASMB)
-
Citizens JMP Starts Assembly Biosciences (ASMB) at Market Outperform
-
Assembly Biosciences (ASMB) PT Raised to $39 at Guggenheim
-
H.C. Wainwright Assumes Assembly Biosciences (ASMB) at Buy
-
Assembly Biosciences prices $175 million equity financing with Gilead
-
Assembly Biosciences (ASMB) Misses Q2 EPS by 133c
-
Assembly Biosciences reports interim data for hepatitis delta drug trial
-
Assembly Biosciences (ASMB) Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
-
Guggenheim Starts Assembly Biosciences (ASMB) at Buy
-
Assembly Biosciences (ASMB) Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
-
Assembly Biosciences (ASMB) Reports Positive Interim Phase 1a Results from Trial of ABI-1179
-
H.C. Wainwright Reiterates Neutral Rating on Assembly Biosciences (ASMB)
-
Assembly Biosciences (ASMB) Reports Interim Phase 1b Results from Clinical Trial of ABI-4334
-
Assembly Biosciences (ASMB) Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
-
Assembly Biosciences (ASMB) Misses Q3 EPS by 151c
-
H.C. Wainwright Reiterates Neutral Rating on Assembly Biosciences (ASMB)
-
Mizuho Reiterates Outperform Rating on Assembly Biosciences (ASMB)
-
Assembly Biosciences (ASMB) Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
-
Jefferies Upgrades Assembly Biosciences (ASMB) to Buy
-
Assembly Biosciences (ASMB) Misses Q2 EPS by 198c
-
Assembly Biosciences (ASMB) Announces $12.6M in Equity Financings

